Eli Lilly and Company is making headlines with a staggering 170% price increase for its weight-loss drug, Mounjaro, in the UK ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company (NYSE:LLY ...

My name is Louise, and I am addicted to Mounjaro. I feel amazing - super healthy, energised, and happier in my skin than I ...

None of this is surprising — especially when at least 500,000 Brits are currently taking Mounjaro and Wegovy via private prescription. For many, the prospect of going cold turkey or forking out up to ...

A good deal rests on the race to develop a weight-loss pill that will widen the market beyond today's injectable "fat jabs".

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 billion. The midpoint suggests a 35% increase in sales for the full year.